Round Table
Safety and efficacy of gene transfer by electroporation: localized and controlled delivery can elevate gene therapy
A Round Table event
An industry-academia-regulators (EMA&FDA) EBTT2024 round table on cell-based therapies and gene transfer by electroporation – time to capitalize on human genome project? The aim of the round table is to bring together industry, regulators and academia to identify gaps in knowledge for developing and optimizing medical treatments.
Webinar: live online and on-site
15:15-17:30 (CET), November 14, 2024 | University of Ljubljana – Ljubljana, Slovenia
Round Table event: “Safety and efficacy of gene transfer by electroporation: localized and controlled delivery can elevate gene therapy”
Please note: Attendance is free and open to anyone interested, however, registration for both online or on-site participation is mandatory. On-site presence is limited due to limited space available.
Tentative programme and list of speakers
- Gerrard Abbate – Inomagen
- Ruggero Cadossi – IGEA, Italy: Medical device for clinical gene therapy
- Maja Čemažar – Institute of Oncology, Slovenia: pDNA number of copies expressed
- Paulo Garcia – Kytopen, USA: genome engineering
- Mauro Giacca – King’s College London, UK: heart regeneration
- Loree Heller – USF, USA: Immunogenicity/DNA sensors
- Richard Heller – USF, USA: mRNA vs pDNA
- David Ho – Columbia University, USA: scaling up to humans
- Rachel Liberatore – Renbio, USA: pDNA distribution in vivo
- Lea Rems – UL, Slovenia: gene transfection for heart tissue regeneration (ERC project)
- Marie-Pierre Rols – CNRS, France: Intracellular transport – how pDNA escapes from endosomes
- David Sourdive – Cellectis, USA: gene editing for cell-based therapies
(speakers/panelists in italics are still to be confirmed)